Citius Pharmaceuticals is trading at $0.74 (5.2% down) in after-hours trading, easing back after a strong multi-day rally driven by positive commercial updates.
- The stock surged on August 5 after the company reported 78% quarterly growth in new LYMPHIR accounts and improving commercial traction.
- Recent weakness likely reflects profit-taking and normal volatility following the company-specific news-driven surge.
- The pullback follows a period of significant double-digit gains recorded during regular trading hours.